Septerna (NASDAQ:SEPN) Stock: Insider Alan Ezekowitz Sells 81,820 Shares

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz sold 81,820 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total value of $3,934,723.80. Following the transaction, the director owned 35,600 shares in the company, valued at approximately $1,712,004. This trade represents a 69.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Septerna Stock Up 1.8%

Shares of NASDAQ:SEPN traded up $0.74 during trading on Friday, reaching $42.60. 337,791 shares of the company traded hands, compared to its average volume of 421,986. The company’s 50 day moving average is $40.46 and its two-hundred day moving average is $33.12. The firm has a market capitalization of $2.03 billion, a PE ratio of -33.02 and a beta of 2.20. Septerna, Inc. has a 52 week low of $19.69 and a 52 week high of $53.34.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative return on equity of 14.98% and a negative net margin of 61.29%. The company had revenue of $18.88 million for the quarter, compared to analyst estimates of $20.78 million. As a group, research analysts anticipate that Septerna, Inc. will post -1.45 EPS for the current year.

Analysts Set New Price Targets

SEPN has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Septerna from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright boosted their target price on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. Wells Fargo & Company upped their price target on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. Finally, JonesTrading increased their price target on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.44.

Key Headlines Impacting Septerna

Investors following SEPN have been watching these headlines:

• Positive Sentiment: Analysts raised expectations for Septerna’s SEP-479 program, prompting a fair-value increase. The more optimistic outlook could support investors’ expectations for the company’s pipeline. Septerna fair-value lift as analysts raise SEP-479 expectations
• Positive Sentiment: Stifel Nicolaus raised its price target on SEPN, while another report said the shares reached a new 52-week high following an analyst upgrade—signals that may reinforce positive sentiment. Stifel Nicolaus price-target boost Shares reach a 52-week high following analyst upgrade
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 target. Its revisions were mixed: it raised its FY2027 loss estimate to a smaller loss of $1.34 per share, but lowered its FY2026 estimate to a larger loss of $1.48 per share and also cut estimates for Q4 2026 and Q1 2027. Septerna analyst and stock information

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the business. Checkpoint Capital L.P. bought a new position in shares of Septerna in the 3rd quarter valued at $2,504,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Septerna during the 3rd quarter worth $232,000. First Trust Advisors LP lifted its position in shares of Septerna by 129.4% during the 3rd quarter. First Trust Advisors LP now owns 17,750 shares of the company’s stock worth $695,000 after buying an additional 10,011 shares during the last quarter. Voya Investment Management LLC bought a new stake in shares of Septerna during the 3rd quarter worth $565,000. Finally, Russell Investments Group Ltd. boosted its stake in Septerna by 8.6% in the third quarter. Russell Investments Group Ltd. now owns 43,683 shares of the company’s stock valued at $1,709,000 after buying an additional 3,474 shares in the last quarter.

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.